FI945437A0 - Kiinteitä tebufelonidispersiokoostumuksia - Google Patents

Kiinteitä tebufelonidispersiokoostumuksia

Info

Publication number
FI945437A0
FI945437A0 FI945437A FI945437A FI945437A0 FI 945437 A0 FI945437 A0 FI 945437A0 FI 945437 A FI945437 A FI 945437A FI 945437 A FI945437 A FI 945437A FI 945437 A0 FI945437 A0 FI 945437A0
Authority
FI
Finland
Prior art keywords
tebufelon
solid
dispersion compositions
dispersion
compositions
Prior art date
Application number
FI945437A
Other languages
English (en)
Swedish (sv)
Other versions
FI945437A (fi
Inventor
Gary Robert Kelm
Douglas Joseph Dobrozsi
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of FI945437A publication Critical patent/FI945437A/fi
Publication of FI945437A0 publication Critical patent/FI945437A0/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI945437A 1992-05-19 1994-11-18 Kiinteitä tebufelonidispersiokoostumuksia FI945437A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/885,932 US5281420A (en) 1992-05-19 1992-05-19 Solid dispersion compositions of tebufelone
PCT/US1993/004050 WO1993023022A1 (en) 1992-05-19 1993-04-30 Solid dispersion compositions of tebufelone

Publications (2)

Publication Number Publication Date
FI945437A FI945437A (fi) 1994-11-18
FI945437A0 true FI945437A0 (fi) 1994-11-18

Family

ID=25388020

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945437A FI945437A0 (fi) 1992-05-19 1994-11-18 Kiinteitä tebufelonidispersiokoostumuksia

Country Status (6)

Country Link
US (1) US5281420A (fi)
EP (1) EP0641199A1 (fi)
JP (1) JPH10512845A (fi)
CA (1) CA2135603C (fi)
FI (1) FI945437A0 (fi)
WO (1) WO1993023022A1 (fi)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2281697A (en) 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
GB2289624B (en) * 1994-05-19 1998-03-18 Euro Celtique Sa Laxative compositions
DE19545043A1 (de) * 1995-12-02 1997-06-05 Scherer Gmbh R P Pharmazeutische Präparate zur oralen Anwendung und Verfahren zu ihrer Herstellung
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
IE981008A1 (en) * 1998-12-02 2000-06-14 Fuisz Internat Ltd Microparticles Containing Water Insoluble Active Agents
FR2792546B1 (fr) * 1999-04-26 2003-01-03 Rhodia Chimie Sa Composition solide comprenant au moins un tensioactif a bas point de fusion
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
AU2001263813A1 (en) * 2000-04-03 2001-10-15 F.Hoffmann-La Roche Ag Concentrated solutions of carvedilol
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2002064121A1 (en) * 2001-02-13 2002-08-22 Astrazeneca Ab Novel modified released formulation
CA2444116C (en) * 2001-05-03 2009-01-20 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
CA2452056C (en) * 2001-07-02 2011-11-01 Elan Corporation, Plc. Compositions of bioactive material particles dispersed in a continuous solid encapsulating material
EP1448567B1 (en) * 2001-09-10 2009-12-30 Tibotec Pharmaceuticals Method for the preparation of hexahydro-furo 2,3-b furan-3-ol
CA2474838C (en) * 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004069180A2 (en) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
DE602004028023D1 (de) * 2003-08-29 2010-08-19 Lifecycle Pharma As Tacrolimus enthaltende feste dispersionen
ATE531368T1 (de) 2003-08-29 2011-11-15 Veloxis Pharmaceuticals As Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
US20080109751A1 (en) * 2003-12-31 2008-05-08 Alias Systems Corp. Layer editor system for a pen-based computer
US20060177403A1 (en) * 2005-02-08 2006-08-10 L'oreal Cosmetic/dermatological compositions comprising a derivative of glucose and of vitamin F and A specific surfactant
FR2881647B1 (fr) * 2005-02-08 2007-03-30 Oreal Composition cosmetique ou dermatologique contenant un derive de glucose et de vitamine f et un tensioactif specifique
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
ES2335922T3 (es) * 2005-09-23 2010-04-06 F.Hoffmann-La Roche Ag Nueva formulacion de dosificacion.
KR101405545B1 (ko) 2005-11-28 2014-07-03 마리누스 파마슈티컬스 ganaxolone 제형, 이의 제조방법 및 용도
DK2081435T3 (en) 2006-09-22 2016-08-15 Pharmacyclics Llc INHIBITORS OF BRUTON'S TYROSINKINASE
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
WO2008145143A1 (en) 2007-05-30 2008-12-04 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
MX2010002712A (es) 2007-09-10 2010-06-09 Calcimedica Inc Compuestos que modulan calcio intracelular.
EP2042165A1 (de) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
BRPI0917719A2 (pt) 2008-08-27 2019-11-19 Calcimedica Inc compostos que modulam cálcio intracelular
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
TWI510238B (zh) 2010-02-17 2015-12-01 Lifecycle Pharma As 穩定化他克莫司(tacrolimus)組合物
US20130149346A1 (en) * 2010-03-08 2013-06-13 ratiopharm GmbH Graf-Arco-Strasse 3 Dabigatran etexilate-containing pharmaceutical composition
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
SI3104853T1 (sl) 2014-02-10 2020-03-31 Respivant Sciences Gmbh Zdravljenje s stabilizatorji mastocitov za sistemske motnje
EP3725311A1 (en) 2014-02-10 2020-10-21 Respivant Sciences GmbH Methods for the treatment of lung diseases with mast cell stabilizers
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
WO2016004369A1 (en) * 2014-07-02 2016-01-07 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
EP3454945B1 (en) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
SG11201901679XA (en) 2016-08-26 2019-03-28 Curtana Pharmaceuticals Inc Inhibition of olig2 activity
CN110139646A (zh) 2016-08-31 2019-08-16 瑞思皮万特科学有限责任公司 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US11382897B2 (en) 2017-11-07 2022-07-12 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
EP3706736A4 (en) 2017-11-10 2021-08-11 The Regents of the University of Michigan ASH1L DEGRADATION AGENTS AND METHODS OF TREATMENT THROUGH THEM
CA3084809A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
JP2021527064A (ja) 2018-06-07 2021-10-11 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Prc1阻害剤及びそれを用いた治療方法
AU2019310118A1 (en) 2018-07-27 2021-03-11 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
US20200069742A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
WO2020160113A1 (en) 2019-02-01 2020-08-06 Myos Rens Technology Inc. Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
EP3937938A1 (en) 2019-03-15 2022-01-19 Unicycive Therapeutics Inc. Nicorandil derivatives
WO2022010537A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Gas41 inhibitors and methods of use thereof
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024086613A2 (en) 2022-10-19 2024-04-25 Myos Corp. Myogenic compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition
US2988484A (en) * 1956-07-24 1961-06-13 Drew & Co Inc E F Alcohol soluble pharmaceutical compositions
US3308217A (en) * 1965-02-09 1967-03-07 Lowy Lawrence Method of granulating materials for subsequent forming into tablets
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3857933A (en) * 1969-10-17 1974-12-31 Hoechst Ag Process for the manufacture of a drug dosage form permitting controlled release of active ingredient
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
GB1598458A (en) * 1977-04-01 1981-09-23 Hoechst Uk Ltd Tableting of microcapsules
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
US4454152A (en) * 1980-05-07 1984-06-12 Hoffmann-La Roche Inc. Methoxsalen dosage forms
JPS5953410A (ja) * 1982-09-20 1984-03-28 Fujisawa Pharmaceut Co Ltd 新型ソフトカプセル剤
LU84515A1 (fr) * 1982-12-09 1984-10-22 Oreal Composition stable pour corticotherapie locale a forte concentration hydrocortisone solubilisee
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
DE3437599A1 (de) * 1984-10-13 1986-04-17 Dolorgiet GmbH & Co KG, 5205 St Augustin Ibuprofen enthaltende weichgelatinekapseln und verfahren zu ihrer herstellung
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
JPS61221131A (ja) * 1985-03-28 1986-10-01 Eisai Co Ltd 吸収促進したユビデカレノン含有組成物
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4708966A (en) * 1986-06-27 1987-11-24 The Procter & Gamble Company Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US4847071A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
US4847303A (en) * 1987-11-23 1989-07-11 The Procter & Gamble Company Tert-butylphenyl compounds useful as anti-inflammatory agents
US4849428A (en) * 1987-11-23 1989-07-18 The Procter & Gamble Company Cyclic anti-inflammatory derivatives of di-tert-butylphenol compounds, compositions and use
US4936074A (en) * 1988-11-17 1990-06-26 D. M. Graham Laboratories, Inc. Process for preparing solid encapsulated medicament
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
DK0431659T3 (da) * 1989-11-22 1994-05-16 Procter & Gamble Farmaceutiske tebufelon-sammensætninger

Also Published As

Publication number Publication date
EP0641199A1 (en) 1995-03-08
FI945437A (fi) 1994-11-18
US5281420A (en) 1994-01-25
JPH10512845A (ja) 1998-12-08
WO1993023022A1 (en) 1993-11-25
CA2135603C (en) 1998-09-22
CA2135603A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
FI945437A (fi) Kiinteitä tebufelonidispersiokoostumuksia
DE69325158D1 (de) Photokromische Zusammensetzung
DE69423670D1 (de) Siloxy-aluminoxan-Zusammensetzungen
DE69326743D1 (de) Tintenzusammensetzungen
DE69311550T2 (de) Sulfopolymer/vanadiumoxid - antistatische zusammensetzungen
KR950703926A (ko) 화장제 조성물(Cosmetic Composition)
DE69305255D1 (de) Beschichtungszusammensetzungen
DE69314838T2 (de) Bindemittelzusammensetzung
DE69310957D1 (de) Organosiliconzusammensetzungen
NO933467D0 (no) Ioderte aroyloksykarboksamider
DE69123586D1 (de) Modifizierte Dispergierzusammensetzungen
ITMI920347A0 (it) Composizioni poliolefiniche termosaldabili
DE69313922D1 (de) Polypropylene-Copolyphthalamid Zusammensetzungen
BR9406627A (pt) Composições antiparasiticas
BR9307800A (pt) ComposiçÕes anticárie
DE69322346D1 (de) Fotoresist-Zusammensetzungen
DE69320891D1 (de) Pestizide Zusammensetzung
DE69217904T2 (de) Zusammensetzung
DE69123585T2 (de) Modifizierte Dispergierzusammensetzungen
DK0599461T3 (da) Hærdelige sammensætninger
EE9800168A (et) Tahked kompositsioonid
FI934360A (fi) Synergistiska antimalariakompositioner innehaollande benflumetol
NO934230D0 (no) Vaskemiddelblandinger
DK0582699T3 (da) Pigmentsammensætning
ITMI921277A0 (it) Composizioni fungicide